Pfizer, Moderna and COVID-19
Pfizer convinces US Patent Office to cancel two Moderna COVID-19 vaccine patents
Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U.S. Patent Office tribunal that two patents Moderna accused them of infringing were invalid.
Moderna Inc. expects to launch a personalized cancer vaccine that it’s developing with Merck & Co. by 2027, one of its top ...
The Trump administration is reviewing a contract extended to Moderna in the final days of the Biden administration.
The Trump administration confirmed it is reevaluating a $590 million human bird flu vaccine contract awarded to Moderna in ...
The FDA canceled a vaccine advisory committee meeting to discuss influenza virus strains that should be included in shots for ...
Moderna is one of the pharmaceutical companies best known for developing the messenger RNA vaccine against Covid-19.
The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.
Moderna, Inc. (NASDAQ:MRNA) shares rose for a second day on Wednesday, adding 15.94 percent to finish at $35.21 apiece as ...
Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...
US health officials are reevaluating a $590 million contract for bird flu shots that the Biden administration awarded to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback